Table 3 Table of characteristics of included studies
Author year, country | Reported PROM (s) | Clinical presentation (Sample size) (Ankle brachial index cut-off) | Age (years) | Gender (% males) | Timing of PROM (s) assessment | Concomitant treatment |
|---|---|---|---|---|---|---|
Chetter 1997, UK [19] | EQ-5D SF-36 NHP | Peripheral arterial disease (n = 235) | 68◊ | 61 | Baseline, week 1 | NR |
(NR) | ||||||
Chong 2002, UK [20] | EQ-5D ICQ SF-36 WIQ | Intermittent claudication (n = 124) | 71◊ | 61 | Baseline, week 2, month 3 | conservative medical treatment; percutaneous transluminal angioplasty |
(≤0.9) | ||||||
Coyne 2003, USA [26] | EQ-5D PAD symptom scale, SF-36, WIQ (self-administered and telephone-administered) | Peripheral arterial disease (n = 60) | 67 | 78 | Baseline, day 4, 7, 14 and 28 | NR |
(<0.9, at rest) | ||||||
Gulati 2009, UK [21] | SF-36 SF-8 | Peripheral arterial disease (n = 193) | 66◊ | 70 | Baseline; at week 2 | NR |
(NR) | ||||||
Izquierdo-Porrera 2005, USA [27] | SF-36 WIQ | Intermittent claudication | 71 | 91 | Baseline, at week 1 | exercise rehabilitation |
(n = 80) (<0.97, at rest; < 0.85, 0.85 during recovery from exercise)) | ||||||
Mazari 2010, UK [25] | EQ-5D SF-6D VascuQoL | Intermittent claudication (n = 178) | 70◊ | 60 | Baseline, at month 1, 3, 6, 12 | transluminal angioplasty, supervised exercise program, or combined treatment |
McDermott 1998, UK [28] | WIQ | Intermittent claudication (n = 146a) | 71.4 | 57 | Baseline | NR |
(≤0.9, at rest) | ||||||
Mehta 2006b, UK [22] | EQ-5D SF-36 SIPic VascuQol | Intermittent claudication (n =70) | 70◊ | 54 | Baseline, at month 6 | Percutaneous transluminal angioplasty (n =47); Conservative medical therapy (n = 23). |
(NR) | ||||||
Morgan 2001, UK [23] | SF-36 VascuQol | Peripheral arterial disease (n = 39) | 67◊ | 62 | Baseline, at week 4 | general advice, medical treatment, angioplasty (n = 4); bypass surgery (NR) |
(NR) | ||||||
Regensteiner 1990, USA [29] | WIQ | Intermittent claudication (n = 26) | 59 (exercise group); 64 (surgery group) 61 (control group) | NR | Baseline, at week 1, 6 and 12 | supervised exercise (n = 10); bypass surgery (n = 7) |
(<0.90, at rest; < 0.85, after exercise) | ||||||
Smith 2007, Australia [18] | SF-36 AUSVIQOL | Intermittent claudication (n = 71) | 72.8 | 68 | Baseline, at month 1 | NR |
(NR) | ||||||
Spertus 2004, USA [30] | WIQ PAQ SF-36 | Peripheral arterial disease (n = 44) | 68 | 55 | Baseline; at week 2 and 8 | Peripheral revascularization |
(NR) | ||||||
Tew 2013c, UK [24] | WIQ | Intermittent claudication | 65 | 81 | Baseline, within days 7 to 10 of first visit | NR |
(n = 37) | ||||||
(≤0.9, at rest) | ||||||
Treat-Johnson 2012, USA [31] | PADQOL POMS SF-36 WIQ | Peripheral arterial disease (n = 295) | 67.9 | 75 | Baseline; follow-up (not specified) | NR |
(NR) |